You're sitting in a cardiologist's office. The echocardiogram is done. The doctor taps a screen, nods, and says, "Your ejection fraction is 45 percent Took long enough..
You nod back. Because of that, you have no idea what that means. You just know it doesn't sound like a hundred.
Here's the thing — most people don't. And that's a problem, because that number? It's one of the clearest windows into how your heart is actually doing. Not how you feel. Not what your blood pressure read at the pharmacy kiosk. The ejection fraction tells you how much blood your left ventricle pushes out with each beat. And whether that number sits at 60 or 35 changes everything about what comes next Most people skip this — try not to..
What Is Ejection Fraction
Ejection fraction — EF for short — is a percentage. It measures how much blood the left ventricle ejects with each contraction compared to how much was in there to begin with Still holds up..
Simple math. Kind of.
If your ventricle holds 100 milliliters at rest and pushes out 60, your EF is 60 percent. That's why if it pushes out 35, your EF is 35 percent. That's normal. That's not.
The left ventricle is the workhorse. The right ventricle matters too, but it's the left side that gets the spotlight in clinical practice. Worth adding: it's the chamber that sends oxygen-rich blood to your brain, your muscles, your kidneys — everywhere. When someone says "heart function percentage," they're almost always talking about left ventricular ejection fraction (LVEF) And that's really what it comes down to..
It's not a score out of 100
This trips people up. In practice, they hear "50 percent" and think: failing grade. But a healthy heart doesn't empty completely. It never has. Here's the thing — a normal EF lands somewhere between 50 and 70 percent. Anything in that range means the pump is doing its job Turns out it matters..
Below 50? That's where the categories start to matter.
Why It Matters
EF isn't just a number on a report. On top of that, it guides treatment decisions. Plus, it shows up in guidelines for heart failure staging. It determines whether you qualify for certain medications, devices like ICDs, or even advanced therapies like transplant evaluation. It influences how aggressively your doctor manages blood pressure, cholesterol, diabetes.
And it predicts outcomes.
A persistently low EF — especially under 35 — carries a higher risk of sudden cardiac death, hospitalization, and progression to advanced heart failure. But here's what most people miss: a normal EF doesn't mean your heart is fine.
You can have heart failure with a perfectly normal ejection fraction. It's called HFpEF — heart failure with preserved ejection fraction. The muscle pumps okay, but it's stiff. It doesn't relax well. On the flip side, pressure builds up. Fluid backs into the lungs. You get short of breath, swollen ankles, fatigue — all with an EF of 60 Worth keeping that in mind..
So EF matters. But it's not the whole story.
How It's Measured
Echocardiogram is the most common way. Here's the thing — non-invasive. So ultrasound. Takes 30 to 45 minutes. The sonographer captures images, the machine calculates volumes, and out pops a number.
But — and this is important — echo has variability. Two different readers might give you 52 and 48. Same study. That's why guidelines use ranges, not single cutoffs It's one of those things that adds up. Worth knowing..
Other methods:
- Cardiac MRI — gold standard for accuracy. Especially good when echo windows are poor (obesity, lung disease). No radiation.
- Nuclear stress test (MUGA scan) — used less now, but still around. Good for serial tracking during chemo.
- CT angiography — can calculate EF, but not the primary reason you'd get one. Day to day, - Left ventriculography — invasive. Consider this: done during a heart cath. Rarely used just for EF anymore.
If you've had more than one test and the numbers don't match, don't panic. Ask your doctor which one they trust most. Usually it's the trend that matters, not a single snapshot.
The Classification System
Guidelines from the ACC/AHA and ESC break EF into categories. They've evolved. Here's the current framework:
Normal EF: 50–70%
Pump function is preserved. But again — symptoms can still exist. Diastolic dysfunction, valvular disease, amyloidosis, hypertensive heart disease — all can hide behind a normal number That alone is useful..
Mildly reduced EF: 41–49%
This used to be a gray zone. Now it's its own category: HFmrEF (heart failure with mildly reduced ejection fraction). It matters because some medications that help at lower EFs — like SGLT2 inhibitors — have shown benefit here too Not complicated — just consistent..
Reduced EF: 40% or below
This is HFrEF (heart failure with reduced ejection fraction). The muscle is weak. The pump struggles. This is where guideline-directed medical therapy (GDMT) becomes critical — beta blockers, ACEi/ARB/ARNI, MRAs, SGLT2 inhibitors. The full quartet.
And within reduced EF, there's further stratification:
- Mildly reduced: 35–40%
- Moderately reduced: 30–35%
- Severely reduced: under 30%
Why the splits? Here's the thing — because device therapy kicks in at specific thresholds. That's why an ICD for primary prevention typically requires EF ≤35% on optimal meds for at least 3 months. CRT (cardiac resynchronization therapy) has its own criteria — usually EF ≤35%, wide QRS, specific bundle branch block patterns.
Recovered EF
This one gets overlooked. Someone starts at 25%, gets on meds, improves to 55%. Their EF "recovered." But they still have a history of cardiomyopathy. They still need meds. Stopping treatment because the number looks good now? That's how you end up back in the hospital.
What Most People Get Wrong
"My EF is 55%, so I'm fine."
Maybe. But if you're breathless climbing stairs, waking up gasping, gaining three pounds overnight — your EF isn't the only metric. Diastolic dysfunction is real. Valve disease is real. Pericardial constraint is real. Don't let a normal number dismiss your symptoms But it adds up..
"My EF dropped from 60 to 50. That's a 10% decline!"
It's a 10-percentage-point drop. Not a 10% decline. And echo variability alone can swing 5–7 points. Look at trends over 6–12 months. One study means very little.
"Low EF means I can't exercise."
Wrong. Cardiac rehab exists for a reason. Supervised, graded exercise improves outcomes in HFrEF. It's Class I recommendation. The key is supervised at first — then a lifelong habit.
"EF is the only number that matters."
Nope. Filling pressures (E/e' ratio), left atrial size, right ventricular function, tricuspid regurgitation, pulmonary artery pressures — all add context. A cardiologist looks at the whole echo report. Not just the bolded number at the top Most people skip this — try not to..
What Actually Helps
If your EF is reduced, the evidence is clear. That said, four drug classes. All of them. Not one or two.
- ARNI (sacubitril/valsartan) — preferred over ACEi/ARB if tolerated. Start low. Watch potassium and kidneys.
- Beta blocker — carvedilol, metoprolol succinate, bisoprolol. Target doses matter. Up-tit
…titration should be gradual, typically every 2–4 weeks, aiming for the target doses proven in mortality trials (carvedilol 25 mg bid, metoprolol succinate 200 mg daily, bisoprolol 10 mg daily). If heart rate or blood pressure limits further uptitration, the highest tolerated dose still confers benefit and should be maintained That's the part that actually makes a difference..
-
Mineralocorticoid receptor antagonist (MRA) — spironolactone or eplerenone are indicated for patients with EF ≤ 35% who remain symptomatic despite ACEi/ARB/ARNI and beta‑blocker therapy, provided serum potassium < 5.0 mmol/L and creatinine < 2.5 mg/dL (men) or < 2.0 mg/dL (women). Start low (spironolactone 12.5 mg daily or eplerenone 25 mg daily) and monitor labs within 1–2 weeks, then monthly for the first three months and thereafter every 3–6 months Not complicated — just consistent. Simple as that..
-
SGLT2 inhibitor — dapagliflozin 10 mg daily or empagliflozin 10 mg daily reduce cardiovascular death and heart‑failure hospitalizations across the EF spectrum, including HFrEF. They can be initiated irrespective of diabetes status, after checking eGFR ≥ 30 mL/min/1.73 m². No routine dose titration is required; begin at the full recommended dose and reassess renal function and volume status after 2–4 weeks It's one of those things that adds up. That's the whole idea..
Adjunctive measures that reinforce GDMT
- Diuretics for volume overload: loop agents (furosemide, torsemide, bumetanide) titrated to achieve euvolemia; monitor weight daily and adjust promptly.
- Hydralazine/isosorbide dinitrate in African‑American patients with NYHA III–IV on optimal therapy, or when ACEi/ARB/ARNI is contraindicated.
- Ivabradine for patients in sinus rhythm with heart rate ≥ 70 bpm despite maximally tolerated beta‑blocker, EF ≤ 35%, and persistent symptoms.
- Vericiguat (soluble guanylate cyclase stimulator) may be added after a recent worsening heart‑failure event in those already on GDMT.
Device therapy considerations
When EF remains ≤ 35% after at least 3 months of maximally tolerated GDMT, evaluate for:
- ICD for primary prevention of sudden cardiac death, provided life expectancy > 1 year. Because of that, - CRT‑D or CRT‑P if QRS ≥ 150 ms with left bundle branch block morphology (or QRS ≥ 130 ms with non‑LBBB and EF ≤ 35%) and symptomatic HF despite GDMT. - Cardiac contractility modulation or baroreceptor activation in select patients ineligible for ICD/CRT.
Monitoring and follow‑up
Structured heart‑failure clinics improve adherence and outcomes. Practically speaking, visits every 1–3 months during titration, then every 3–6 months once stable, should include:
- Symptom assessment (NYHA class, dyspnea scales, orthopnea, paroxysmal nocturnal dyspnea). - Vital signs, weight, blood pressure, heart rate. Still, - Labs: electrolytes, renal function, hemoglobin, natriuretic peptides (BNP/NT‑proBNP) for trend analysis. - Echocardiogram annually or sooner if clinical status changes.
Patient empowerment
Education about medication purpose, side‑effect signals (e.g., cough with ACEi, hyperkalemia with MRA/ARNI, genital infections with SGLT2i), and the importance of never discontinuing GDMT without clinician guidance reduces readmissions. Encourage participation in cardiac rehabilitation, sodium restriction (< 2 g/day), fluid moderation as advised, regular aerobic activity, and vaccination (influenza, COVID‑19, pneumococcal).
Short version: it depends. Long version — keep reading.
Conclusion
Ejection fraction remains a cornerstone for classifying heart failure and guiding therapy, yet it is only one facet of a complex syndrome. Optimal management hinges on initiating and uptitrating the four pillar drug classes—ARNI/ACEi/ARB, beta‑blocker, MRA, and SGLT2 inhibitor—while individualizing diuretic strategies, considering device implantation when thresholds are met, and addressing comorbidities and lifestyle factors. Continuous monitoring, patient education, and a multidisciplinary approach transform a reduced EF number
from a static prognostic marker into a dynamic target for life‑prolonging intervention. By systematically applying evidence‑based pharmacotherapy, leveraging device therapy in appropriately selected patients, and fostering a partnership that prioritizes self‑care and early symptom recognition, clinicians can meaningfully alter the natural history of heart failure with reduced ejection fraction—extending survival, reducing hospitalizations, and preserving the quality of life that patients value most.
